Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database
Authors:
- Nienke E. BakkerNBNienke E. Bakker
- on behalf of the KIGS Steering CommitteeOCon behalf of the KIGS Steering Committee
Open Access
- 16 February 2017
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (5) , 1702-1711
Abstract
Context: Longitudinal data of children with Prader-Willi syndrome (PWS) treated with genotropin were registered in the Pfizer International Growth Database (KIGS). Objective: To evaluate efficacy and safety of growth hormone (GH) treatment in a large group of children with PWS. Design: Data registered in KIGS from 1987 to 2012. Setting: Worldwide retrospective cohort study. Patients: Patients included 522 prepubertal children treated with GH for three years and 173 children who had reached adult height. Safety analysis included 2332 children. Intervention involved GH treatment. Main outcome measure: Height standard deviation score (SDS), body mass index (BMI) SDS, occurrence of serious adverse events, and deaths reported in KIGS. Results: In prepubertal children, mean (standard deviation) height SDS improved to −0.31 (1.34) (P < 0.05) during three years of GH treatment. In the adolescent group, height SDS improved until the start of puberty to −0.22 (1.31) (P < 0.05) but had a loss of −0.77 (0.81) during puberty, resulting in a mean adult height SDS of −1.19 (1.37). Total height gain was 0.95 (1.32) SDS. BMI SDS increased in the prepubertal group from 1.11 (2.09) to 1.53 (1.43) (P < 0.05) and did not significantly change in the adolescent group, who had a BMI SDS at an adult height of 1.78 (1.26). KIGS contained 12 death reports. Conclusions: GH treatment in children with PWS significantly improves linear growth. BMI remains on average below +2 SDS, in contrast to the natural course of increasing obesity in PWS. Safety should be closely monitored in children with PWS, with and without GH treatment.Keywords
This publication has 47 references indexed in Scilit:
- Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2013
- The effect of growth hormone on sleep‐related cardio‐respiratory control in Prader–Willi syndromeActa Paediatrica, 2012
- Long-Term Growth Hormone Therapy Changes the Natural History of Body Composition and Motor Function in Children with Prader-Willi SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2010
- Scoliosis in Prader-Willi syndrome: prevalence, effects of age, gender, body mass index, lean body mass and genotypeArchives of Disease in Childhood, 2008
- Prader–Willi syndromeEuropean Journal of Human Genetics, 2008
- Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader–Willi syndromeClinical Endocrinology, 2008
- Gastric Rupture and Necrosis in Prader‐Willi SyndromeJournal of Pediatric Gastroenterology and Nutrition, 2007
- An Update of the Swedish Reference Standards for Weight, Length and Head Circumference at Birth for Given Gestational Age (1977‐1981)Acta Paediatrica, 1991
- PRADER‐WILLI SYNDROME IN A SWEDISH RURAL COUNTY: EPIDEMIOLOGICAL ASPECTSDevelopmental Medicine & Child Neurology, 1991
- Variations in pattern of pubertal changes in girls.Archives of Disease in Childhood, 1969